ERBB2 and neoplasm: Altogether, the superior recognition, infiltrating, proliferating and killing capacities of ErbB2-CAR CIK cells compared to WT CIK cells was proven in 16-hour cytotoxicity analyses, in tumor monolayers and tumor spheroids, conditions which best mimic in vivo-like models in which tumor cells outnumber immune effector cells.